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ABSTRACT 
Background: 
Dextromethorphan (DXM) is a synthetic opioid analogue, similar to codeine that has antitussive 
effect but no opiate-like analgesic activity. It is widely used as an over-the-counter cough suppressant 
available in various cough and cold preparations; it is one of the often overlooked types of substance 
abuse by adolescents and young adults in the United States and around the world. So, the present study 
aims to investigate the side effects of the DXM abuse (sub-chronic and lethal doses) on the immune 
functions in rats. 
 Material and Methods: 
The rats were divided into three equal groups, the first one served as control, and the second and 
third were treated. Treated groups received oral doses of DXM which increasing per 10 days (double 
dose) for a month.  
Results 
We examined the sub-chronic and lethal effects of DXM administration on the cellular immune 
responses in rats. T cell stimulator, Phytohemagglutinin showed a significant suppress on lymphocytes  of 
peripheral blood proliferation and a highly significant decrease  on phagocytic and killing of S. aureus by 
PMN and macrophage cells. Moreover, it induced a significant decrease in serum IL-6, and IFN-γ levels, 
but, it exhibited a highly significant increase in serum IL-10 level throughout the period of experiment. In 
addition, it induced also a significant decrease in the production of cortisol during the experimental time 
except the last period of treatment in the 3
rd group, where, serum cortisol level gradually return to normal 
level.  
Conclusion: 
These results suggest that sub-chronic and lethal doses of DXM administration in rats disturbed 
cellular  immune  responses,  exhibited  potent  anti-inflammatory  actions,  suppressed  of  leukocytes 
dependent production  of cytokines such as IL-6 and IFN-γ. Moreover, it  has some  effects  on serum 
cortisol concentration presumably via blockade of NMDA receptors.  
Key words: Dextromethorphan, IFN-γ, IL-10, IL-6, Phagocytosis, Lymphocytes transformation, 
Cortisol, Albino rat. 
 
Introduction 
Dextromethorphan  (DXM)  is an  over-the-
counter  (OTC)  cough  suppressant  commonly 
found  in  cold  medications
  (1).  DXM  is  often 
abused in high doses by adolescents to generate 
euphoria and visual and auditory hallucinations 
(1,2).  DXM  is  an  antitussive  that  has  been 
proposed  to  have  potential  utility  in  the 
treatment  of  various  neurological  disorders 
(3). 
Moreover, it has been suggested to be useful in 
attenuating tolerance to opioids, reducing opioid 
withdrawal  and  inhibiting  the  reinforcing 
properties of a variety of abused drugs 
(4). Aside 
from  its  effects, DXM is  essentially  devoid  of 
other opioid-type effects 
(5). 
However,  it  interacts  at  non-opioid  sites 
and  possesses  other  pharmacological  activity. 
For example, DXM is both a substrate and an 
inhibitor of CYP450 2D6 
(6). It is metabolized to 
an active metabolite dextrorphan, which, along 
with  DXM,  antagonizes  the  N-methyl-D-
aspartate  receptors  (NMDA),  producing 
phencyclidine  (PCP)  -  like  effects,  inhibiting 
serotonin  reuptake,  competing  for  serotonergic 
receptors,  and  eliciting  adrenergic  effects  by 
inhibiting peripheral and  central catecholamine 
uptake 
(7).  It  is  well  known  that  the  central 
nervous  system  and  behavior  can  influence 
immune function 
(8).  Immunomodulatory Changes Induced  By High Doses Of Dextromethorphan… 
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DXM is commonly formulated with other 
agents,  such  as  antihistamines,  analgesics  and 
decongestants  that  can  complicate  and  worsen 
drug effects, especially in overdose. Symptoms 
of  mild  to  moderate  toxicity  include 
hallucinogenic  and  dissociative  effects, 
agitation,  somnolence,  ataxia,  mydriasis, 
diaphoresis, and tachycardia; severe intoxication 
can  lead  to  seizures  and  death
  (1).  DXM  is 
formulated  as  a  hydrobromide  salt  which  can 
result  in  bromide  toxicity,  especially  with 
chronic  abuse
  (2).  The  risk  for  serotonin 
syndrome can also occur with concomitant use 
of competitive inhibitors of CYP450 2D6, such 
as  selective  serotonin  reuptake  inhibitors  (the 
most potent being paroxetine) and amphetamine 
analogues,  including  methyl-enedioxy-meth-
amphetamine 
(9). 
In  rats  and  monkeys,  DXM  produces 
discriminate  stimuli  that  generalize  to  PCP, 
ketamine  and  other  noncompetitive  NMDA 
receptor antagonists 
(10). Clinically, high doses of 
DXM can induce psychotropic effects/euphoria 
(11). DXM also binds with high affinity to other 
sites, including sigma binding sites 
(9), nicotinic 
receptors and calcium channels 
(12). It has been 
suggested  that  the  discriminative  stimulus 
effects DXM more closely resemble the effects 
of  drugs  that  interact  at  sigma  receptors 
compared with other sites 
(10).         
The  sympathetic  nervous  system  has 
been  implicated  in  the  modulation  of  splenic 
natural killer (NK) cell activity. In some cases, 
psychoactive compounds suppressed splenic NK 
cell  activity  and  mitogen-induced  lymphocyte 
proliferative  responses 
(13).  There  is  a  critical 
need for current information regarding the scope 
of  DXM  abuse  in  order  to  understand  the 
significance  of  the  problem.  In  addition,  little 
has been reported in the literature on effects of 
higher  doses  of  DXM  on  immune  system  in 
rodents. So, the present study aim to investigate 
oral  administration  of  the  DXM  abuse  side 
effects on the immune function after exposure to 
its sub- chronic and lethal doses in rats. 
MATERIAL AND METHODS 
Animals 
Male albino rats of the Sprague-Dawley, 
60 days  old and 150 to 180 g  in  weight  were 
used  as  experimental  animals  throughout  the 
present  work.  They  were  supplied  from 
Theodore  Billharz  Research  Institute  (TBRI). 
Upon arrival, the rats were individually caged in 
a colony room, where a reversed day-night (12 
hr)  cycle  was  maintained  through  artificial 
illumination. Rats received access free to both 
food pellets (protein 21% and energy 2950 K.C.) 
and water throughout the experiments. 
Drug  
TUSSILAR  (Dextromethorphan  hydro-
bromide  tablets)  (DXM),  produced  by  Kahira 
Pharma. & Chem. IND. Co. Cairo, Egypt. 
Experimental design and DXM treatment: 
The animals (63) were divided into three 
equal  groups  (n=21).  The  first  one  served  as 
control.  While,  the  second  and  third  were 
treated.  Control  received  0.1  ml  saline  for  the 
same  period  of  treatment.  Treated  groups  
received  daily  oral  doses  of  DXM  which 
increasing  per  10  days  (double  dose)  for  a 
month, In the 2
nd  group, the rats  received daily 
oral doses of DXM, starting with the dose 12.5 
mg/kg/day and ending with 50 mg/kg/day. In the 
3
rd  group,  the  rats  were  treated  with  DXM, 
starting with the dose 25 mg/kg/day and ending 
with 100 mg/kg/day. Seven animals from each 
group were sacrificed per 10 days. These daily 
doses were calculated for rats according to Paget 
and Barnes, 
(14). 
Measurement of body weight 
Each  rat  was  weighted  on  10,  20,  30 
days to study the  changes rate in body weight 
throughout the experimental period. 
Serum IFN-γ, IL-10 and Il-6 
To  investigate  the  effect  of  DXM 
administration on T-helper (Th) cell population 
of  lymphocytes  [Th1  cytokine  (IFN-γ)/Th2 
cytokine  (IL-10)]  cell  function  and  on  this 
response,  immunoassay  kits  {Abnova  (cat  # 
KA0274.V.01),  PBL  Biomedical  Laboratories 
(product  #  43500-1,  V.1.3)}  were  used  to 
determine serum concentration of  IFN-γ  
(15) and 
IL- 10 
(16) as an indicator of Th1 and Th2 cell 
function,  respectively.  IL-6  level,  Max-
Discovery
TM  ratIL-6  ELISA  test  kit  (catalog  # 
2203  reference  #2202-01)  is  designed  for 
quantitative determination for the concentration 
of  ratIL-6  in  serum,  plasma,  and  cell  culture 
supernatant. Sensitivity: 60  pg/ml. 
Cortisol level:  
The  calbiotech,  Inc.  (CBI)  cortisol 
ELISA  kit  is  intended  for  the  quantitative Hanan Rabei 
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measurement  of  cortisol  in  serum  or  plasma 
(Catalog No. C0103S)  
(17). 
Phagocytosis and killing assay 
Blood  collected  in  heparin-coated 
universal  bottles  from  experimental  animals 
were  used  to  prepare  leukocytes  for  bacterial 
phagocytosis.  The  heparinized  blood  samples 
were treated with 0.83% ammonium chloride to 
lyses red blood cells, washed three times  with 
cold phosphate buffer solution (PBS) at PH 7.2 
and  resuspended  in  minimal  essential  medium 
(MEM) with 0.5% inactivated fetal calf serum to 
give  a  final  concentration  of  10
8  viable 
polymorphonuclear  leukocytes  (PMN)  and 
macrophage  cells  per  ml
  (18).  A  strain  of 
coagulase-positive  Staphylococcus  aureus       
(S. aureus) isolated in the laboratory was used. 
The  bacteria  were  washed  in  PBS  and 
resuspended  in  (MEM)  to  give  a  final 
concentration of 5x10
8 bacteria per ml.  
Assay of phagocytosis 
The mixtures of bacteria (S. aureus) and 
leukocytes were incubated at 37
oC for two hours 
with regular stirring and then the mixtures were 
centrifuged  at  200xg  for  5  min.  at  4
oC.  The 
supernatants  were  used  to  estimate  the 
percentage  of  bacteria  phagocytosed  using  the 
formula: 
Phagocytosis  %  =  (CFU  before  incubation  - 
CFU after incubation)/CFU before incubation             
Assay of bacterial killing  
Samples  of  MEM  containing  bacteria  
(S.  aureus)  alone  and  containing  mixtures  of 
bacteria  (S.  aureus)  and  leukocytes  were 
incubated  at  37
oC  for  two  hours.  Then  the 
samples were treated with one cycle of freezing 
with liquid nitrogen and thawing. The number of 
colony forming units (CFU) was then estimated 
by the  method  of Woldehiwet and Rowan 
(18). 
The percentage of bacteria killed was estimated 
according to the formula: 
Bacterial killing % = CFU in sample containing 
bacteria - CFU in sample containing bacteria & 
leukocyte  mixture / CFU in sample  containing 
bacteria alone. 
Splenocytes preparation 
The  spleen  of  rats  were  individually 
removed  and  placed  in  cold  culture  media 
(RPMI-1640)  containing  100  U/ml  penicillin, 
100g/ml,streptomycin, 200 mM Glutamine/100 
mM Na pyruvate. Each spleen was gently teased 
loose and passed through a stainless steel mesh 
(40µm  pores)  to  remove  cell  aggregates  and 
connective  tissue.  Each  suspension  was 
centrifuged at + 4
oC  for 10  min at 400xg. To 
lysis the RBCs, the  pellet was resuspended in 
1ml sterile  dist. water (hypotonic solution)  for 
30  sec,  then  40  ml  of  RPMI  medium  were 
immediately  added  and  the  suspension  was 
centrifuged  at+4
oC  for  5  min  at  400xg.  Cells 
were  then  washed  twice  with  ice-cold  RPMI-
1640  and  resuspended  for  counting.  Counting 
and assessment of viability were performed by 
trypan blue exclusion method 
(19). 
Lymphocytes transformation test using MTT:  
MTT (3, 4, 5- dimethylthiazoyl -2 , 5 -
diphenyl  tetrazolium  bromide)  colorimetric 
analysis  was  used  to  measure  the  proliferation 
rate of lymphocytes. The effect of the drug on 
lymphocyte  transformation  was  performed 
according  to  Rai-Elblhaa  et  al., 
(20).  Briefly, 
heparinized blood samples were taken from all 
rat groups and layered carefully on the surface 
of Ficol-hypaque solution in a ratio of 2/1 and 
centrifuged at 400xg at 4
oC for 30 min. to give 
packed blood cells with granulocytes, interface 
layer  (monocytes  and  lymphocytes)  and  upper 
plasma  layer.  The  interface  layer  containing 
monocytes  and  lymphocytes  was  carefully 
aspirated using sterile glass Pasteur pipette, and 
then  placed  in  sterile  tubes  containing  2ml 
RPMI-1640 media. Cells were washed 3 times 
with  RPMI-1640  media  by  centrifugation  at 
1800  r.p.m.  at  4
oC.  After  the  last  wash  the 
sediment lymphocytes were resuspended in one 
ml  of  RPMI-1640  containing  10%  FCS. 
Lymphocytes were setting in 96 well TC plate 
(150µl/well) the first row was left free as blank, 
where in the other wells number of lymphocytes 
was adjusted to 1x10
6/well. Each well received 
50 µl PHA (5µg/ml) as mitogen. The plate was 
incubated  at  37
oC,  5%  Co2  for  72h.  In  humid 
incubator, MTT solution was added in a ratio of 
1/10 of total sample then incubated at 37
 oC, 5% 
Co2  for  4h.  After  incubation,  lysis  buffer  was 
added  (50µl/well) over  night  in  incubator then 
the  absorbance  was  recorded  at  470nm. 
Stimulation index (SI) = mean cpm of triplicate 
test  cultures  /  mean  cpm  of  corresponding 
replicate of control rat. 
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Statistical analysis:  
Data were presented as mean ± SE. The 
statistically significant differences of treated and 
control animals were evaluated by Student’s t-
test or one-way analysis of variance (ANOVA). 
A  P  value  of  less  than  0.05  was  considered 
statistically significant 
(21). 
RESULTS 
Effect of DXM administration on body weight 
Daily administration of DXM doses for 
30 days in the 2
nd and 3
rd treated groups in rats 
caused  a  non  significant  difference  on  body 
weight  during  the  experimental  period  when 
compared to the control group (Fig.1). 
Effects on cellularity of spleen 
Spleen cellularity of both DXM treated 
groups  showed  a  significant  effect  (P  ≤  0.05) 
versus control rats. It started by decreasing  the 
number of splenocytes after 10 and 20 days in 
the  2
nd  and  3
rd  treated  groups  then  increasing 
after 30 days of both treated groups (Fig. 2 ). 
Effects on mitogen stimulation  
The results of PHA (5µg/ml) stimulated 
lymphocytes  of  peripheral  blood  appeared  a 
highly significant suppress (P ≤ 0.001) of both 
DXM  treated  groups  in  a  dose  dependence 
throughout  treatment  period  as  compared  to 
control group (Fig. 3). 
Effects  of  phagocytosis  and  killing  of  S. 
aureus  induced  polymorphonuclear  and 
macrophage cells in the peripheral blood. 
As shown in Figs. (4,5), the results  of 
both  DXM  treated  rats  showed  a  highly 
significant decrease (P  ≤ 0. 01) on phagocytic 
and  killing  of  S.  aureus  by  PMN  and 
macrophage cells versus control animals. 
Effects on serum IFN-γ, IL-10 and IL-6 
The results of IL-6 production in serum 
exhibited  a  significant  decrease  (P  ≤  0.  01) 
throughout the period of administration of both 
the  2
nd  and  3
rd  treated  group  as  compared  to 
control rats   Fig. (6). Moreover, as shown  in 
Fig.  (7),  the  production  of  IFN-γ  in  serum 
exhibited a highly significant suppress (P  ≤ 0. 
01) with increasing doses of both DXM treated 
rats. While, the administration of DXM induced 
a highly significant increase (P ≤ 0. 01)  in the 
production of serum IL-10 during the period of 
treatment (Fig.8).  
 
The  assessment  of  cortisol  production  in 
serum  
Daily administration of both DXM treated 
groups induced a significant decrease (P ≤ 0. 01) 
in  the  production  of  cortisol  during  the 
experimental  time  except  the  last  period  of 
treatment  in the 3
rd  group,  where, the  level  of 
cortisol  production  gradually  return  to  normal 
level as the control group (Fig.9).  
DISCUSSION 
In the present study, the results showed 
the effects of DXM on cellular immune response 
in  rats.  T  cell  stimulator,  phytohemagglutinin 
induced  suppression  effect  on  lymphocyte 
proliferation  of  peripheral  blood  of  rats  in  the 
treated  groups.  These  results  are  in  agreement 
with  the  findings  of  other  investigators  who 
reported  that  high  doses  of  DXM  can  induce 
psychotropic  effects/euphoria 
(22).  Furthermore, 
psychoactive compounds suppressed splenic NK 
cell  activity  and  mitogen-induced  lymphocyte 
proliferative  responses
  (13).  But  other 
investigators 
(23)  who  studied  that  the  chronic 
effect  of  dextromethorphan  (DXM)  on  the 
cellular  immune  responses  in  mice.  T  cell 
stimulator,  phytohemagglutinin  did  not  show 
significant effect on lymphocyte proliferation. 
The results of the current study revealed 
that the administration of DXM with increasing 
its  doses  in  two  treatment  groups  for  30  days 
induced  suppression  in  the  activity  level  of 
phagocytosis and killing of the PMN cells and 
macrophage cells of blood induced by S. aureus 
bacteria in vitro. These results are in line with 
the  findings  of  other  investigators 
(13)  who 
documented that DXM attenuated production of 
superoxide  and  intracellular  reactive  oxygen 
species  in Kupffer cells and  neutrophils. Real-
time  RT-PCR  analysis 
(24)  revealed  also  that 
DXM administration suppressed the expression 
of a variety of inflammation-related genes such 
as  macrophage  inflammatory  protein-2,  CXC 
chemokine,  thrombospondin-1,  intercellular 
adhesion  molecular-1,  interleukin-6,  the 
production  of  tumor  necrosis  factor-alpha, 
monocyte  chemo-attractant  protein-1,  and 
superoxide  in  macrophage  cell  culture  after 
stimulation. DXM also decreased the expression 
of genes related to cell-death pathways, such as 
the  DNA  damage  protein  genes  GADD45  and 
GADD153 
(25).  Moreover,  these  effects  on Hanan Rabei 
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cytokines production in dose dependent pattern 
and duration of the drug administration showed 
also  suppression  of  mitogen  -  induced 
lymphocyte proliferative responses, total number 
of  splenocytes  and  the  activity  level  of 
phagocytosis and killing of the PMN cells and 
macrophage cells of blood induced by S. aureus 
bacteria in vitro. 
In the present study, treatment of normal 
rats with two different doses of DXM caused a 
significant reduction in the level of Th1 cytokine 
(IFN-γ) and IL-6, but increased   in the level of 
Th2 cytokine (IL-10) in serum. From previous 
studies, Hu et al., 
(26) who revealed that IFN-γ 
enhances  macrophage  responses  to  other 
inflammatory  factors  such  as  toll  like  reaction 
(TLR) ligands. TLR activation of macrophages 
also induces cytokines of the IL-6/IL-12 family 
that  regulate  the  transition  from  innate  to 
acquired immunity. While, IL-10 is produced as 
part of the homeostatic response to inflammation 
and played a critical role in limiting the duration 
and  intensity  of  immune  and  inflammatory 
reactions 
(27).  
Furthermore, in rats and monkeys, DXM 
produced discriminate stimuli that generalize to 
PCP  and  ketamine  as  noncompetitive  NMDA 
receptor antagonists 
(10). Aside, in our previous 
studied 
(28)  treatment  of  normal  rats  with 
ketamine in subanesthetic and lethal doses for 15 
days induced significant reduction in the level of 
Th1  cytokine  (IFN-γ)  and  a  non  significant 
change in the level of Th2 (IL-10) in serum  in 
dose dependence pattern. 
In harmony with previous studies, DXM 
produced  similar  effects  as  noncompetitive 
NMDA receptor antagonists. The results of the 
current study revealed that treatment of normal 
rats with two different doses of DXM displayed 
a significant reduction in the level of cortisol in 
serum. These results are in agreement with other 
investigators who studied that NMDA receptors 
are involved in general glutamatergic excitatory 
action.  What makes DXM so interesting is that 
the behavioral changes caused by varying doses 
of the drug can be traced directly to proportional 
amounts  of  receptor  occupation.  Sigma1 
receptors are also located throughout the body.  
Research  suggests  that  sigma1  receptors  can 
inhibit  tumor  growth  as  well  as  inhibit  the 
immune system 
(29). 
Furthermore,  many  investigators 
reported that noncompetitive NMDA antagonists 
such  as  PCP,  ketamine  and  DXM  produced 
profound  behavioral  effects  and  stimulate  the 
hypothalamo-  pituitary-adrenal  (HPA)  axis  in 
the rat. This response is centrally mediated and 
not due to direct stimulatory effects at the level 
of the pituitary or adrenal gland 
(9). 
Moreover,  another  investigator 
(30) 
reported that the effect of ketamine (KET) and 
cocaine  (COC)  interaction  on  corticosterone 
secretion can be explained, in part, by indirect 
effect  of  KET.  It  significantly  prevented  the 
stimulatory  effect  of  COC  on  serum 
corticosterone  concentration  presumably  via 
blockade of NMDA receptors. In addition, the 
NMDA  receptor  stimulation  is  essential  for 
corticosterone  release  induced  by  COC 
treatment  in  rats.  Reduction  of  serum 
corticosterone concentrations by KET correlates 
with  reversal  of  COC-induced  effects  on 
leucocytes  counts,  serum  IgM,  and  IL-10 
concentrations. 
On  the  other  hand,  some  investigators 
reported  that  DXM  and  dextrorphan  stimulate 
the HPA axis in the rat; however, acute dose of 
DXM induced a significant  increase in plasma 
ACTH  and  cortisol  levels  after  30  min  of  the 
administration of the drug, but both of them non 
significant change in the plasma after 120 min of 
acute  single  dose  when  compared  to  control 
group 
(29). Some studies are  disagreement  with 
the current study. When, in an earlier study, he 
(31) did not find any change in the plasma level of 
corticosterone after administration  dextrorphan, 
but the dose used in their study (1 mg/kg) was 
far lower than the dose that caused a significant 
increase in the Pechnick and Poland experiment 
(29)  (i.e.,  30  mg/kg).  To  our  knowledge  the 
present  study  is  the  first  report  to  show  its 
effects  on  the  rat,  (i.e.,  12.5  to  100  mg/kg 
throughout 30 days). 
  From  the  aforementioned  studies,  it 
could  be  concluded  that  the  DXM  abuse 
perturbed cellular immune responses, exhibited 
potent anti-inflammatory actions, suppressed of 
leukocytes  dependent  production  of  cytokines 
such as IL-6 and IFN-γ. Moreover, it effect on 
serum  cortisol  concentration  presumably  via 
blockade of NMDA receptors that this is similar 
to  the  immunosuppressive  effects  caused  by Immunomodulatory Changes Induced  By High Doses Of Dextromethorphan… 
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ketamine and phencyclidine. Physicians
 need to 
be aware of the abuse potential of DXM, as well 
as  the
  availability  of  drug  information  on  the 
internet. Adolescents
 can download instructions 
on making illicit substances, as well
 as purchase 
the  ingredients  necessary  to  create  these 
dangerous
 products. Finally, physicians need to 
remember that DXM found
 as a component of a 
large number of nonprescription cough and
 cold 
remedies,  usually  in  combination  with 
decongestants,  antihistamines,
  and  acetamino-
phen.  These  other  compounds  have  toxic 
properties
 that are independent of dextromethor-
phan and may require specific
 treatment.
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Fig. (1 ):The change in the body weight (g) of rats at various time intervals  (days)  after 
              administration of  dextromethorphan.  
            The data are expressed as mean ﾱ S.E . 
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Fig.( 2):Total cell number of splenocytes  of rats at various time intervals  (days) after 
             dextromethorphan administration. The data are expressed as mean ﾱ S.E. * P ≤ 0.05 
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Fig.(3): Proliferation responses of lymphocytes of peripheral blood of rats after concentration of 
             PHA (5µg/ml) at various  time intervals (days) of dextromethorphan administration.  
The data are expressed as mean ﾱ S.E . *** : P ≤ 0.001 
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Fig.(4): The percentage of phagocytic bacteria by the leukocytes in the peripheral blood 
             lymphocytes  of  rats after dextromethorphan administration.  
The data are expressed as mean ﾱ S.E . ** : P ≤ 0.01 
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Fig.(5): The percentage of bacteria killed by the leukocytes in the peripheral blood lymphocytes 
             of  rats after dextromethorphan administration. 
The data are expressed as mean ﾱ S.E .** : P ≤ 0.01     
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Fig. (6 ): Level of IL-6 in serum of rats after dextromethorphan administration. 
The data are expressed as mean ﾱ S.E .*** : P ≤ 0.001 
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Fig. (7 ): Level of IFN- ɤ  in serum of rats after dextromethorphan administration.  
The data are expressed as mean ﾱ S.E .**: P ≤ 0.01    *** : P ≤ 0.001     
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Fig.(8): Level of IL-10 in serum of rats after dextromethorphan administration . 
The data are expressed as mean ﾱ S.E .* : P ≤ 0.05    ** : P ≤ 0.01     
    
*  * 
** 
* 
0 
10 
20 
30 
40 
50 
60 
70 
10  20  30 
C
o
r
t
i
s
o
l
 
l
e
v
e
l
 
(
n
g
/
m
l
)
 
Experimental period (days) 
Saline group  DXM treated group (12.5mg/kg)  DXM treated group (25 mg/kg) 
Fig.(9 ): Level of cortisol in serum of rats after dextromethorphan administration . 
The data are expressed as mean ﾱ S.E . .**: P ≤ 0.01  *** : P ≤ 0.001 
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